

Press release

VERDOT welcomes BioProcess360 Partners as new shareholder, with a €10 million investment to support the company's next phase of growth alongside majority shareholders Qualium Investissement and Lauxera Capital Partners

Paris, Riom, Delray Beach, Florida, January 14th, 2025 – VERDOT, supported by its majority shareholders, Qualium Investissement and Lauxera Capital Partners, is pleased to announce a €10 million investment from BioProcess360, a specialized, US-based investment fund focused on the bioprocessing and life sciences sectors.

With this strategic investment, BioProcess360 becomes an active shareholder in VERDOT alongside Qualium Investissement, Lauxera Capital Partners, and existing legacy shareholders, reinforcing the Group's ambitions to drive commercial scale and expand its global footprint.

Since Qualium and Lauxera took control of VERDOT in July 2022, the company has undergone significant transformation, laying a solid foundation for future growth. Key milestones include the internationalization of the management team, strengthening of the operational workforce, the establishment of a US subsidiary, several new product/platform launches both underway and planned and a comprehensive revamp of VERDOT's commercial strategy.

BioProcess360's strategic investment will further enable VERDOT to strengthen its commercial reach, scale its manufacturing capabilities and unlock new product opportunities. With extensive experience in supporting high-growth companies in the bioprocessing and life sciences sectors, BioProcess360's team brings complementary expertise and networks that will contribute to Verdot's continued success.

Chris Major, Founding Partner at BioProcess360, commented: *"VERDOT has decades of history as a leading technology partner for traditional monoclonal antibody processes. We have been impressed by their ability to listen to the needs of customers and to develop novel technologies that specifically address the unmet needs in new molecular entities like nucleic acids and gene therapy. We are incredibly excited to partner with Qualium, Lauxera and other legacy shareholders by contributing €10 million capital to support VERDOT future growth. The investors, board and leadership team are a winning combination focused around delivering exceptional customer outcomes. Together we look forward to helping our customers reduce time to market, improve process efficiencies and help bring lifesaving therapies to patients."*

Charles Ruban, President and CEO of VERDOT added: *"This investment marks a pivotal moment for VERDOT as we advance our strategic initiatives and expand our global reach. The partnership with BioProcess360, alongside Qualium, Lauxera, and historical shareholders, will provide the resources and expertise needed to consolidate our market position and deliver on our clients' high expectations."*

Pierre Moustial, Founder of Lauxera Capital Partners and Chairman of the Board commented: *"We are thrilled to welcome BioProcess360 and Chris Major as shareholders of Verdot. Chris brings*

invaluable experience and exceptional insight that will be instrumental in driving the company's growth and seizing the many exciting opportunities ahead."

Jacques Pancrazi, Deputy Managing Director of Qualium Investissement highlighted: *"With the support of BioProcess360 and their €10 million investment, we are confident that VERDOT will accelerate its growth trajectory and continue to lead in its field. We look forward to this next exciting chapter."*

About VERDOT

VERDOT, established in 1950 and headquartered in Riom, France, stands at the forefront of downstream bioprocessing technology. VERDOT focuses on innovative purification solutions for the biopharmaceutical industry, including chromatography columns, and custom and standardized chromatography and tangential flow filtration (TFF) systems. VERDOT systems and columns are employed in the purification, separation and concentration of biomolecules such as monoclonal antibodies, vaccines, viral vectors (e.g., AAV and lentivirus), and mRNA-based therapeutics.

VERDOT partners with industry leaders in biopharma, research and development, early-stage biotech, and contract development and manufacturing organizations (CDMOs), offering unparalleled expertise across the entire drug development workflow. From initial exploration to the manufacturing of market-ready biologics, VERDOT offers tailored, high-quality purification technologies that enable clients to accelerate time-to-market of groundbreaking therapies.

More information: www.verdot-biotechnologies.com

About Qualium Investissement

Qualium Investissement is a major long-standing private equity firm with €1.5 billion in funds under management. Originally formed in 1998 as the private equity investment arm of Caisse des Dépôts et Consignations (CDC), Qualium is now independent and owned by its team, with continuous support from CDC and a solid base of reputable limited partners. Qualium prides itself in being the preferred partner to SME managers and business owners with ambitious development plans to transform their growing businesses into French and international leading SMEs. Qualium is currently investing through its third fund, with a total size of €535 million.

More information: www.qualium-investissement.com

About Lauxera Capital Partners

Lauxera Capital Partners, founded in January 2020, is an independent healthcare-focused asset management company based in Paris and San Francisco. Lauxera promotes the growth of European HealthTech companies and has invested €262 million in 12 fast-growing businesses across Europe and the US through its first fund, Lauxera Growth I. Lauxera is currently raising its second fund, with a first closing of over €300 million completed in late 2024. The firm leverages deep sector expertise, close ties to the US healthcare ecosystem, and hands-on operational experience to drive international expansion for its portfolio companies.

More information: <https://lauxera.com/fr>

About BioProcess360 Partners

BioProcess360 Partners are unique Life Sciences investment partners with proven expertise in delivering high-growth strategies for innovations in downstream processing.

Headquartered in Florida, USA, they provide inflection, growth capital and hands-on guidance from industry leaders to support the growth of emerging, innovative technologies in Bioprocessing.

More information: www.BioProcess360.com

*
* *